BioSpace News Archive

VFMCRP receives EU approval for Tavneos ® for the treatment of ANCA-associated vasculitis.

PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, announced that it has appointed Laurie Keating as Chair of the company’s Board of Directors.

ViaCyte, Inc. today announced the appointment of Alyssa Levin as Chief Financial Officer and addition of Lisa E. Porter, M.D., to its Board of Directors.

Lyra Health, the leading provider of innovative Workforce Mental Health solutions for employers, today announced it has acquired ICAS World, a global employee assistance program provider with a network of care professionals who offer localized support for people in more than 155 countries and 66 languages.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium.

Akari Therapeutics, Plc, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, announced that the U.S. Food and Drug Administration has agreed, via a Type C meeting, to the clinical use of nomacopan derived from a next generation manufacturing process.

NanoVibronix Inc today announced it has filed three U.S. patent applications with the U.S. Patent & Trademark Office related to its SAW technology and indwelling medical devices to protect targeted new product launches and improvements to existing medical devices.

MediPrint™ Ophthalmics announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium, a leading eye care conference.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is supporting the American Heart Association’s multi-year effort to generate awareness among cross-disciplinary specialties and improve survival rates from cardiovascular implantable electronic device (CIED) infections.

Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that patient enrollment of its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma is complete.